Printer Friendly
The Free Library
19,573,962 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

3M Drug Delivery Systems to Implement ``Rapid Screening Process''.


Business Editors & Health/Medical Writers

ST. PAUL St. Paul

as a missionary he fearlessly confronts the “perils of waters, of robbers, in the city, in the wilderness.” [N.T.: II Cor. 11:26]

See : Bravery
, Minn.--(BUSINESS WIRE)--Nov. 28, 2001

- NCE NCE Networks of Centres of Excellence
NCE New Chemical Entity (pharmaceutical research)
NCE Normal Curve Equivalent
NCE New Civil Engineer (UK Journal)
NCE Non-Commercial Educational
NCE New Century Energies
 Candidates Quickly Analyzed for `Go/No Go' -

3M Drug Delivery Systems (DDS (1) (Digital Data Storage) See DAT.

(2) (Data Dictionary System) See QuickBuild and OpenDDS.

(3) (Dataphone Digital S
) Division today announced implementation of a new "Rapid Screening Process" designed to rapidly investigate the suitability of new chemical entities (NCEs) for delivery from a pressurized pres·sur·ize  
tr.v. pres·sur·ized, pres·sur·iz·ing, pres·sur·iz·es
1. To maintain normal air pressure in (an enclosure, as an aircraft or submarine).

2.
 metered dose inhaler inhaler /in·hal·er/ (in-hal´er)
1. an apparatus for administering vapor or volatilized medications by inhalation.

2. ventilator (2).


in·hal·er
n.
 (MDI (1) (Multiple Document Interface) A Windows function that allows an application to display and lets the user work with more than one document at the same time. ). The program, which was successful in a prototype program, lasts about six months and now is available for all potential inhalation drug development partners of 3M Drug Delivery Systems.

Peter Robinson, pharmaceutical program manager for 3M DDS, based in Loughborough, UK, said, "This program is designed in three expedited stages -- preformulation, formulation and manufacturing of one formulation in a one month stability program. At each milestone, DDS holds evaluation meetings with its development partner to decide if the work is `Go/No Go.' " Robinson pointed out that this step-approach is more focused on the needs of the customer, allowing them to receive early notice on the suitability of their NCE in the MDI format. "Previously, inhalation feasibility programs weren't structured to provide evaluative milestones and appreciable payments. We see our Rapid Screening Process as more scientifically efficient, as well as more financially predictable within the budgeting systems of our partners."

According to Robinson, the costs for the three stages of development are split into three separate milestone payments. Projected costs are based only on the activity being undertaken in that particular phase. The program can be halted at any stage depending on discussions with the customer at each milestone meeting. "Customers like this arrangement," said Robinson. "It is fair to them, and enables 3M to quickly determine the developmental value of each entity being tested."

About 3M DDS

3M DDS is a global leader in the development of inhalation and transdermal technologies. As the creator of the first metered-dose inhaler metered-dose inhaler Pharmacology A device used to deliver a specified number of doses of a therapeutic inhalant–eg, β-agonist for asthma , the division has a 45-year history of medical innovation, including introduction of the world's first HFA HFA Harvard Film Archive (Harvard University)
HFA Harry Fox Agency, Inc.
HFA Housing Finance Agency (District of Columbia government)
HFA Hyogo Framework for Action
HFA High-Functioning Autism
 inhalers. Today, 3M DDS components and services are used in over 50 percent of all global MDI devices. Likewise, the company also pioneered the 3M Latitude transdermal drug delivery system, a drug-in-adhesive platform, that can be customized for a variety of therapeutic agents while delivering medication through the patient's skin for up to a week. Over 80 percent of transdermal systems in the United States contain at least one 3M DDS component.

About 3M

3M is a $17 billion technology company with leading positions in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. Headquartered in St. Paul, Minnesota, the company has operations in more than 60 countries and serves customers in nearly 200 countries. 3M businesses share technologies, manufacturing operations, brands, marketing channels and other important resources. 3M is one of the 30 stocks that make up the Dow Jones Industrial Average Dow Jones Industrial Average

The best known U.S. index of stocks. A price-weighted average of 30 actively traded blue-chip stocks, primarily industrials including stocks that trade on the New York Stock Exchange.
 and also a component of the Standard & Poor's 500 Index. Additional information about the company is available on the Internet at http://www.3M.com.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 28, 2001
Words:493
Previous Article:Ptech Inc. Announces Ptech KnowledgeGateway Software for Portal Access to Business and IT Architecture, Analysis, and Operational Information.
Next Article:Multimedia Available: Applied Materials Launches Innovative Nitridation Technology for Advanced Transistor Manufacturing.
Topics:



Related Articles
Merck and Cellomics Sign High Content Screening - HCS - Alliance Agreement.
3M Drug Delivery Systems Division Announces Topical Patch Arthritis Management Platform.
3M Drug Delivery Systems and GlaxoSmithKline Announce Collaboration to Research and Develop New Formulations of Respiratory Medicines.
3M To Manufacture Xopenex HFA Metered-dosed Inhaler.
3M To Manufacture Xopenex HFA Metered-dose Inhaler.
Biotech Molecules Delivered by HFA MDI Inhalation; 3M DDS Research Shows Viability Using Time-Tested Technology.
IVAX Expands U.S. Asthma Products Line Through Agreement With 3M for QVAR Brand Inhaler.
IVAX Expands U.S. Asthma Products Line Through Agreement With 3M For QVAR Inhaler.
3M Announces a Technical Collaboration on New MDI Projects with Novartis; Novartis NCEs and 3M Inhalation Expertise to be Combined.
Planned therapeutic nanny state: no matter the motives, efforts to do routine mental health testing on children in America's schools need to be...

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles